drugset / Trial / NCT05693766
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Phase 2
Recruiting
64 enrolled
Sonya Reid
Agendia · collabSusan G. Komen Breast Cancer Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Timeline
- Start
- 2023-09-28
- Primary completion
- 2027-08-31
- Completion
- 2037-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 2000 mg | Oral |